Therapeutic potential of IL-15 in rheumatoid arthritis.

[1]  C. Díaz-Torné,et al.  Rituximab‐induced interleukin‐15 reduction associated with clinical improvement in rheumatoid arthritis , 2014, Immunology.

[2]  M. Soucek,et al.  Relation of IL‐6, IL‐13 and IL‐15 gene polymorphisms to the rheumatoid factors, anti‐CCP and other measures of rheumatoid arthritis activity , 2014, International journal of immunogenetics.

[3]  T. Waldmann.  The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. , 2013, The journal of investigative dermatology. Symposium proceedings.

[4]  X. Mao,et al.  Systemic Delivery of Small Interfering RNA Targeting the Interleukin-2/15 Receptor β Chain Prevents Disease Progression in Experimental Arthritis , 2013, PloS one.

[5]  Min Zhang,et al.  IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. , 2013, Human immunology.

[6]  Jinming Li,et al.  Strategies for active TNF-α vaccination in rheumatoid arthritis treatment. , 2013, Vaccine.

[7]  P. Mueller,et al.  Disseminated Mycobacterium haemophilum infection in a 72-year-old patient with rheumatoid arthritis on infliximab , 2013, BMJ Case Reports.

[8]  P. Emery,et al.  Targeting Interleukin-6 in Rheumatoid Arthritis , 2013, Drugs.

[9]  J. Choe,et al.  The distinct expressions of interleukin-15 and interleukin-15 receptor α in Behçet’s disease , 2013, Rheumatology International.

[10]  K. Nishida,et al.  Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis , 2012, Case reports in rheumatology.

[11]  M. Soucek,et al.  Circulating cytokine pattern and factors describing rheumatoid arthritis: IL-15 as one of the biomarkers for RA? , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[12]  A. Grzegorzewska,et al.  Disseminated cutaneous Kaposi sarcoma in a patient receiving triptolide/tripdiolide for rheumatoid arthritis , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[13]  Yoshiya Tanaka,et al.  The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. , 2012, Arthritis and rheumatism.

[14]  C. Balagué,et al.  Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant‐induced arthritis model: a translational study , 2012, British journal of pharmacology.

[15]  R. Tsonaka,et al.  Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study , 2012, Annals of the rheumatic diseases.

[16]  W. Dixon,et al.  The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register , 2012, Annals of the rheumatic diseases.

[17]  I. González-Álvaro,et al.  Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis , 2011, PloS one.

[18]  D. Pattanaik,et al.  Breast lymphoma complicating anti-tumor necrosis factor therapy in rheumatoid arthritis. , 2011, Clinical breast cancer.

[19]  Xia Li,et al.  IL-33: a promising therapeutic target for rheumatoid arthritis? , 2011, Expert opinion on therapeutic targets.

[20]  E. Park,et al.  IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. , 2011, Immunology letters.

[21]  Charles Peterfy,et al.  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. , 2011, Arthritis and rheumatism.

[22]  W. Maśliński,et al.  Elevated number of recently activated T cells in bone marrow of patients with rheumatoid arthritis: a role for interleukin 15? , 2010, Annals of the rheumatic diseases.

[23]  X. Zheng,et al.  Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. , 2010, Arthritis and rheumatism.

[24]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[25]  E. Rahme,et al.  Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists , 2010, The Journal of Rheumatology.

[26]  X. Mao,et al.  Interleukin-15 receptor-directed immunotoxins atteunuate disease severity in rat adjuvant arthritis. , 2010, Molecular immunology.

[27]  F. Breedveld,et al.  Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial , 2009, Annals of the rheumatic diseases.

[28]  G. Pavlakis,et al.  Secretion and Biological Activity of Short Signal Peptide IL-15 Is Chaperoned by IL-15 Receptor Alpha In Vivo1 , 2009, The Journal of Immunology.

[29]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[30]  M. Ernst,et al.  Interleukin‐15 stimulates macrophages to activate CD4+ T cells: a role in the pathogenesis of rheumatoid arthritis? , 2009, Immunology.

[31]  M. Weinblatt,et al.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[32]  M. Gadina,et al.  Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity. , 2008, Rheumatology.

[33]  M. Feldmann,et al.  Neutralizing IL‐21 and IL‐15 Inhibits Pro‐inflammatory Cytokine Production in Rheumatoid Arthritis , 2008, Scandinavian journal of immunology.

[34]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[35]  Feifei Zhao,et al.  Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. , 2007, Clinical immunology.

[36]  A. Cope,et al.  The central role of T cells in rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[37]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[38]  A. Hamzaoui,et al.  Levels of IL‐15 in Serum and Cerebrospinal Fluid of Patients with Behçet's Disease , 2006, Scandinavian journal of immunology.

[39]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[40]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[41]  N. Pejnović,et al.  Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis , 2006, Clinical Rheumatology.

[42]  R. González-Amaro,et al.  IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. , 2005, Rheumatology.

[43]  P. Parren,et al.  Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. , 2005, Arthritis and rheumatism.

[44]  J. Zwerina,et al.  Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines , 2005, Annals of the New York Academy of Sciences.

[45]  L. Petrović-Rackov.  Cytokines in rheumatoid arthritis and osteoarthrosis. , 2005, Medicinski pregled.

[46]  T. Yajima,et al.  A novel autoregulatory mechanism for transcriptional activation of the IL‐15 gene by a nonsecretable isoform of IL‐15 generated by alternative splicing , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  T. Strom,et al.  Targeting IL-15 Receptor-Bearing Cells with an Antagonist Mutant IL-15/Fc Protein Prevents Disease Development and Progression in Murine Collagen-Induced Arthritis1 , 2004, The Journal of Immunology.

[48]  I. McInnes,et al.  Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. , 2004, Current opinion in pharmacology.

[49]  J. Kay,et al.  The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. , 2004, Rheumatology.

[50]  F. Emmrich,et al.  Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis , 2004, Rheumatology International.

[51]  M. Harnett,et al.  New strategies to control inflammatory synovitis: interleukin 15 and beyond , 2003, Annals of the rheumatic diseases.

[52]  I. González-Álvaro,et al.  Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. , 2003, Clinical and experimental rheumatology.

[53]  F. Belardelli,et al.  IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation1 , 2001, The Journal of Immunology.

[54]  S. Sierakowski,et al.  Serum cytokines in different histological variants of rheumatoid arthritis. , 2001, The Journal of rheumatology.

[55]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[56]  H. Makino,et al.  Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[57]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[58]  I. McInnes,et al.  Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. , 1998, Journal of immunology.

[59]  T. Waldmann,et al.  The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. , 1998, Journal of immunology.

[60]  R. Brezinschek,et al.  Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo. , 1998, The Journal of clinical investigation.

[61]  T. Waldmann,et al.  Interleukin-2, interleukin-15, and their receptors. , 1998, International reviews of immunology.

[62]  T. Waldmann,et al.  Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[63]  L. Notarangelo,et al.  Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes , 1997 .

[64]  R. Paus,et al.  Interleukin-15 protects from lethal apoptosis in vivo , 1997, Nature Medicine.

[65]  I. McInnes,et al.  Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.

[66]  T. Pohl,et al.  Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. , 1997, Journal of immunology.

[67]  T. Waldmann,et al.  Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Caligiuri,et al.  Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. , 1996, Blood.

[69]  T. Waldmann,et al.  IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. , 1996, Immunity.

[70]  I. McInnes,et al.  The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis , 1996, Nature Medicine.

[71]  R. Dubose,et al.  Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor. , 1995, The EMBO journal.

[72]  R. Perlmutter,et al.  Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation , 1995, Cell.

[73]  N. Copeland,et al.  Chromosomal assignment and genomic structure of Il15. , 1995, Genomics.

[74]  J. Dayer,et al.  Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .

[75]  R. Paxton,et al.  IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. , 1995, Journal of immunology.

[76]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[77]  V. Fung,et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.

[78]  M. Kozak.  A consideration of alternative models for the initiation of translation in eukaryotes. , 1992, Critical reviews in biochemistry and molecular biology.

[79]  M. Kozak,et al.  An analysis of vertebrate mRNA sequences: intimations of translational control , 1991, The Journal of cell biology.

[80]  M. Kozak.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. , 1987, Nucleic acids research.